Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by AstraZeneca < Previous 1 2 3 4 5 6 Next > EVUSHELD™ significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations April 20, 2022 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer April 19, 2022 From AstraZeneca Via Business Wire Tickers AZN ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks April 06, 2022 From AstraZeneca Via Business Wire Tickers AZN Inaugural Asia Summit on Global Health successfully explores healthcare landscape November 25, 2021 From AstraZeneca Via ACN Newswire Inaugural Asia Summit on Global Health opens today November 24, 2021 From AstraZeneca Via ACN Newswire Inaugural Asia Summit on Global Health highlights Hong Kong's advantages November 17, 2021 From AstraZeneca Via ACN Newswire AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees March 24, 2022 From AstraZeneca Via Business Wire Tickers AZN EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies March 21, 2022 From AstraZeneca Via Business Wire Tickers AZN LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer March 16, 2022 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer February 21, 2022 From AstraZeneca Via Business Wire Tickers AZN LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer February 14, 2022 From AstraZeneca Via Business Wire Tickers AZN Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis January 24, 2022 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years January 18, 2022 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer January 18, 2022 From AstraZeneca Via Business Wire Tickers AZN CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen January 17, 2022 From AstraZeneca Via Business Wire Tickers AZN Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen January 17, 2022 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) Data at ASCO GI and GU January 13, 2022 From AstraZeneca Via Business Wire Tickers AZN TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma January 13, 2022 From AstraZeneca Via Business Wire Tickers AZN EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities December 23, 2021 From AstraZeneca Via Business Wire Tickers AZN TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma December 17, 2021 From AstraZeneca Via Business Wire EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study December 16, 2021 From AstraZeneca Via Business Wire Tickers AZN CALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial December 12, 2021 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer December 09, 2021 From AstraZeneca Via Business Wire Tickers AZN EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19 December 08, 2021 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care December 03, 2021 From AstraZeneca Via Business Wire Tickers AZN LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer November 30, 2021 From AstraZeneca Via Business Wire Tickers AZN New Analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention November 18, 2021 From AstraZeneca Via Business Wire Tickers AZN LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia November 17, 2021 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021 November 05, 2021 From AstraZeneca Via Business Wire Tickers AZN SAPHNELO Consistently Reduces Systemic Lupus Erythematosus Disease Activity Regardless of Disease Duration and Prior Treatment November 01, 2021 From AstraZeneca Via Business Wire Tickers AZN < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.